Abbreviations: BMI, body mass index; 17b-HSD, 17b-hydroxysteroid dehydrogenase; E1, estrone; E2, estradiol; E2-FAE, E2 fatty acyl ester; FEI, free estradiol index; IQR, interquartile range; IS, internal standard; LC-MS/MS, liquid chromatography-tandem mass spectrometry; STS, steroid sulfatase; WHR, waist to hip ratio. In conclusion, the changes in adipose tissue E1 and E2 concentrations and the estrogen-35 regulating CYP19A1 and HSD17B1 during the menstrual cycle may be related to 36 dysfunctional local estrogen metabolism in women with breast cancer. 37
0.14 vs. 0.22; 0.09-0.54, P=0.025) were lower in women with breast cancer than in controls. 34
In conclusion, the changes in adipose tissue E1 and E2 concentrations and the estrogen-35 regulating CYP19A1 and HSD17B1 during the menstrual cycle may be related to 36 dysfunctional local estrogen metabolism in women with breast cancer. 37
Introduction 42
In premenopausal women, estrogens are produced both in the ovaries and through peripheral 43 conversion of adrenal precursor androgens [1, 2] . Increased circulating estrogen and androgen 44 concentrations have been linked to premenopausal breast cancer [3] , but the breast cancer 45 risk, unlike in postmenopausal women, may be inversely associated with adiposity [4, 5] . 46
In the breast, the mammary gland and the ductal system are abundantly surrounded by 47 4 and without breast cancer. 66
Methods 67

Subjects and study design 68
We collected AT samples from premenopausal women operated for estrogen receptor-positive 69 breast cancer (mastectomy; n=11) and women undergoing reduction mammoplasty (control; 70 n=17). Detailed clinical information (Table 1 ) was gathered at the preoperative visit and from 71 medical records. Women using oral contraceptives were excluded. 72
Blood samples were obtained preoperatively and processed as described [13] . Two 73 subcutaneous AT samples (1 g each) from the breast specimens were immediately snap frozen 74 in liquid nitrogen [13] . The phase of the menstrual cycle was based on serum progesterone 75 and E2 (luteal phase concentrations >7 nmol/L and 0.37-0.77 nmol/L, respectively). 76
Women with and without breast cancer were comparable in the primary clinical 77 characteristics only waist to hip ratio (WHR) was slightly higher in control women (Table 1) . 78 
Ethical approval 86
The study complies with the Declaration of Helsinki and was approved by the Ethics 87
Committee of Helsinki University Hospital. Informed consent was obtained from all subjects. 88
Quantification of hormones and SHBG 89
For determination of E1, 30 µL of 13 C3-E1 (2.5 nM; IsoSciences) was added as an internal 90 standard (IS) to a 250 mL aliquot of serum or 200 mg of AT homogenized in 1 mL of distilled 91
water. The AT samples were then processed as described in [18] . E1 in serum and purified 92 
E2 and hydrolyzed E2-FAE were analyzed by E2 LC-MS/MS as described [2] with a LOQ of 99 15 pmol/L (S/N=10). Interassay imprecision of endogenous E2-FAE in pooled AT was 15% 100
in nine consequent assays. Interassay variation of the serum control samples was 11% and 101 7.1% for E2, and 6.2% and 18% for E2-FAE, respectively, in nine or ten consequent assays. 102
For serum progesterone, 13 C3-progesterone was added as an IS (IsoSciences) and the samples 103 were extracted with diethylether. Extracts and calibrators (Riedel-deHaën, Buchs, 104 Switzerland) were analyzed on a LC-MS/MS system equipped with an API 3000 triple 105 quadrupole mass spectrometer (PE Sciex, Foster City, CA), an Agilent series 1200 HPLC 106 system with a binary pump (Waldbronn, Germany) and a SunFire C18 column (2.1 x 50 mm; 107 Waters, Milford, MA). The mobile phase was a linear gradient consisting of methanol and 50 108 mM ammonium acetate in water, at a flow rate of 250 uL/min and the gradient was: 0 min, 109 50% methanol; 1.5 min 95% methanol; 5 min 95% methanol; and 5.5-10 min 50% methanol. 
Results
130
Estrone was the predominant estrogen in premenopausal AT, the concentration being 131 approximately three times higher than that of E2 ( Figure 1A , Table 2 ). Adipose tissue 132 concentrations of E1 (P<0.0001), E2 (P<0.0001), and E2-FAE (P<0.0001) were higher than 133 the corresponding serum levels (Figure 1) During the menstrual cycle, the E2 levels in AT followed the changes detected in serum, while 140 E1 and E2-FAE levels did not change significantly (Table 2) findings indicate that estrogen levels may be regulated in AT during the menstrual cycle, our 176 data do not give direct evidence that these fluctuations could be gonadotropin-controlled. 177
In women with breast cancer, follicular phase AT E1 and E2 levels were lower than luteal 178 phase levels, whereas there was no significant difference in control women. Also, in cancer 179 patients, the follicular phase gene expressions of the two estrogen regulating enzymes, 180 CYP19A1 and HSD17B1 were lower than in controls. These findings may imply that estrogen 181 synthesis in the tumor-bearing breast AT is dysregulated. There is evidence that adipocytes 182 near the tumor go through a phenotypic change into cancer-associated adipocytes [27] , which 183 could possibly affect local estrogen production, at least in part explaining our findings. 184
Contrary to our data on postmenopausal women [13] the overall E2 or E2-FAE levels in 185 women with and without breast cancer did not differ. This emphasizes the differences 186 between premenopausal and postmenopausal breast cancer, and the need to take into account 187 hormonal fluctuations when studying premenopausal women. 188
Our study has limitations. We acknowledge the relatively small number of women in our 189 study, which may affect the power in the comparisons between the subgroups. Also The data are expressed as median (range) 1 or n (%) 2 . 308 309 310 
